<?xml version="1.0" encoding="UTF-8"?>
<p>The novel COVID-19 pathology is considered the consequence of a cytokine storm, an excessive and uncontrolled release of pro-inflammatory factors, leading to acute lung injury, acute respiratory distress syndrome, and death [
 <xref rid="B47-jcm-09-02084" ref-type="bibr">47</xref>]. Therefore, anti-inflammation therapy might help prevent further aggravation of the disease. The pharmacological drug classes able to reduce inflammation include non-steroidal anti-inflammatory medication, glucocorticoids, chloroquine and hydroxychloroquine, immunosuppressants, and inflammatory cytokines antagonists (IL-6R monoclonal antibodies, TNF inhibitors, IL-1 antagonists, janus kinase inhibitor (JAK) inhibitors) [
 <xref rid="B47-jcm-09-02084" ref-type="bibr">47</xref>].
</p>
